MTOR and neoplasm: Nevertheless, rather than exclusively targeting mTORC1 component of mTOR pathway, expression analysis profiling of patient-derived TNBC tumours in conjunction with in vivo studies on TNBC mice revealed a higher susceptibility of TNBC to mTOR targeting.